Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old

Next Previous
Trial Profile

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Alemtuzumab (Primary) ; Fludarabine (Primary) ; Melphalan (Primary) ; Stem cell therapies
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 03 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top